Penumbra keeps a two-page list of key thrombectomy opportunities and technologies to innovate that allows it to keep transforming, presently with its computed-assisted vacuum technology (CAVT) for removing clots from the body, CEO Adam Elsesser explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Elsesser sits down with BI analyst Matt Henriksson for an in-depth interview about Penumbra, how CAVT can sense the pressure differentials between clot and blood to suck clot when it’s there and close the valve when not in order to limit blood loss, and how a serendipitous lunch was enough for him to adapt and expand technology originally designed for neuro cases to also treat peripheral disease, which has become Penumbra’s largest and fastest-growing segment.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.